Epigenetics of Cardiac Arrhythmia

Definition

Epigenetic regulation of arrhythmia-susceptibility genes involves heritable changes in gene activity without alterations to the DNA sequence, encompassing non-coding RNA expression, DNA methylation, histone modifications, genomic imprinting, and three-dimensional (3D) genome architecture. These mechanisms modulate the expression of ion channel genes (SCN5A, KCNH2, KCNQ1, KCND3, KCNJ2) and calcium-handling proteins (RYR2, CASQ2), influencing arrhythmia susceptibility independent of — and in interaction with — germline coding mutations.

Key Concepts

Non-coding RNA

• miR-19b — multi-channel regulator and LQTS candidate: miR-19b is a conserved microRNA that simultaneously regulates multiple ion channel-encoding genes. miR-19b deficiency in zebrafish produces prolonged action potentials, severe bradycardia, and arrhythmia susceptibility — phenocopying LQTS. Directly regulated targets include SCN1B (Na channel β1 subunit — upregulated upon miR-19b loss, increasing late INa and prolonging APD) and KCNE4/KCNE1 (upregulated, impairing KCNQ1 function and reducing IKs). Indirectly, KCNA4, KCND3, SCN12B, and CACNA1C are downregulated upon miR-19b reduction. Notably, miR-19b reduction can also rescue the SQTS phenotype in heterozygous zebrafish, demonstrating bidirectional relevance to both LQTS and SQTS. (sources/genetics-va-fcvm-2022 — medium)

• Circulating miRNAs as arrhythmia biomarkers: Circulating miRNAs are stable in plasma and differentially expressed between disease states. miR-133 is elevated in paediatric patients with VT compared with healthy controls. miR-320 plasma levels are significantly higher in idiopathic VT patients than in arrhythmogenic cardiomyopathy (ACM) patients — a potential circulating biomarker to distinguish IVT from ACM. UTR regions of arrhythmia-susceptibility genes (SCN5A, SCN1B) contain miRNA binding sites, and mutations within these UTR regions have been reported. (sources/genetics-va-fcvm-2022 — medium)

• U1 snRNA and KCNH2 splicing regulation: KCNH2 intron 9 is inefficiently spliced in human heart — only 1/3 of precursor mRNA produces functional Kv11.1a; 2/3 produce non-functional C-terminal truncated Kv11.1a-USO isoform. The degree of complementarity between U1 small nuclear RNA (the RNA component of U1 snRNP) and the 5' splice site of intron 9 is the principal determinant of splicing efficiency. A KCNH2 IVS9-2delA mutation found in a large LQTS family switches the entire output to non-functional Kv11.1a-USO. Therapeutic concept: engineering modified U1 snRNA with improved complementarity to the KCNH2 intron 9 splice site significantly restores functional Kv11.1a expression and IKr current in vitro — a potential RNA-based therapy for splicing-defective LQTS. (sources/genetics-va-fcvm-2022 — medium)

DNA Methylation

• SCN5A H558R (rs1805124) — promoter methylation modifier of BrS: H558R is a common SCN5A polymorphism that acts as a genetic-epigenetic modifier of BrS. The molecular mechanisms are dual: (1) at the protein level, H558R repairs abnormal gating kinetics and improves membrane trafficking of co-expressed pathogenic SCN5A variants, reducing phenotype severity; (2) at the epigenetic level, H558R reduces methylation of the SCN5A promoter, increasing SCN5A expression in cardiac tissue and preventing VF. The G allele of H558R is paradoxically associated with QTc prolongation in population studies, reflecting pleiotropic effects. (sources/genetics-va-fcvm-2022 — medium)

• KCNQ1OT1 imprinting and QT interval: KvDMR1 is a differentially methylated region within the KCNQ1 locus that regulates KCNQ1, long non-coding RNA KCNQ1OT1, and CDKN1C through genomic imprinting. KCNQ1OT1 expresses only the paternal allele (maternal allele silenced by methylation). KCNQ1OT1 coordinates chromatin conformation changes and histone modifications to regulate KCNQ1 spatiotemporal expression — making KCNQ1-LQTS appear autosomal dominant rather than maternally transmitted in the adult heart. KCNQ1OT1 rs11023840 AA genotype increases KCNQ1OT1 promoter methylation → prolonged QTc interval — a direct methylation-QT link. Female predominance and maternal transmission distortion remain documented in some KCNQ1-LQTS cohorts, suggesting incomplete resolution of the imprinting mechanism. (sources/genetics-va-fcvm-2022 — medium)

• ATO-induced LQTS — epigenetic drug toxicity mechanism: Arsenic trioxide (ATO), used to treat acute promyelocytic leukaemia, is a known QT-prolonging agent. ATO induces a decrease in KCNQ1OT1 transcription → KCNQ1OT1 silencing inhibits KCNQ1 expression → prolonged AP duration in vitro and LQTS in vivo. ATO also induces miR-133 and miR-1 dysregulation: miR-133 inhibits ERG protein (KCNH2-encoded) → reduced IKr; miR-1 downregulates Kir2.1 (KCNJ2-encoded) → reduced IK1 — producing combined ion channel suppression as the mechanism of QT prolongation. (sources/genetics-va-fcvm-2022 — medium)

Histone Modifications

• KChIP2 expression regulated by H3K4me3: KChIP2 (K⁺ channel-interacting protein 2) is a β-subunit of the Kv4.3 Ito channel that also modulates INa. KChIP2 expression is controlled by H3K4me3 (trimethylation of histone H3 at lysine 4, an active transcription mark) in adult cardiomyocytes. Decreased H3K4me3 → reduced KChIP2 expression → attenuated Ito and INa → prolonged APD → increased ICaL and enhanced contractility. KChIP2 is heterogeneously expressed across the ventricular wall (epicardium > endocardium), contributing to the transmural Ito gradient that underlies normal T-wave morphology. KChIP2 knockout in mice eliminates fast Ito entirely and confers susceptibility to VT. No human KChIP2 coding mutations have been reported, making epigenetic regulation of its expression the clinically relevant mechanism. (sources/genetics-va-fcvm-2022 — medium)

• HEY2 transcriptional regulation by H3K4me3/H3K27ac: HEY2 is a GWAS-validated BrS susceptibility gene and a cardiac transcription factor critical to RVOT development. HEY2 regulates SCN5A expression, cardiac conduction system formation, and expression of transmural potassium channels (Kcnip2/KChIP2, KCND2), shaping the transmural Ito and INa gradient. H3K4me3 and H3K27ac (histone H3 acetylated at lysine 27, an active enhancer mark) bind to the HEY2 promoter and enhancer, governing HEY2 transcription and thus downstream ventricular electrophysiology. (sources/genetics-va-fcvm-2022 — medium)

3D Genome Architecture

• SCN10A enhancer–SCN5A promoter physical interaction: The intronic enhancer (ENHA) in SCN10A physically interacts with the SCN5A promoter via 3D chromatin looping — this interaction is necessary for normal SCN5A in vivo expression. The major allele G of common variant rs6801957 (within ENHA) establishes a conserved T-box transcription factor binding site that promotes enhancer activity. The risk allele significantly reduces SCN5A expression — explaining the GWAS association of rs6801957 with both QRS prolongation and BrS susceptibility. This 3D architectural mechanism provides a functional interpretation for previously unexplained common GWAS variants and illustrates how non-coding regulatory variants in adjacent genes (SCN10A) can modulate key arrhythmia genes (SCN5A). (sources/genetics-va-fcvm-2022 — medium)

• CTCF/cohesin chromatin loops and arrhythmia gene regulation: CTCF and cohesin complexes assemble 3D chromatin loops and maintain topological domain boundaries that restrict functional element interactions. CTCF knockout in animal models causes dysregulated expression of RYR2, KCND2, KCNQ1, SCN5A, and CACNB1 in the ventricle → heart failure, suggesting that chromatin architectural disruption may constitute a broader arrhythmia substrate mechanism. CTCF binding site variants in arrhythmia gene loci remain to be characterised in human disease. (sources/genetics-va-fcvm-2022 — medium)

• KCNH2 locus cis-acting enhancer: A conserved cardiac cis-acting element in the KCNH2 locus regulates KCNH2 expression through physical proximity (chromatin loop) to the KCNH2 promoter. Common GWAS variants associated with LQTS at the KCNH2 locus may disrupt this enhancer, providing a functional mechanism for polygenic QT interval regulation beyond coding mutations. (sources/genetics-va-fcvm-2022 — medium)

Contradictions / Open Questions

• Human translation of zebrafish/murine epigenetic findings: Most epigenetic mechanisms described (miR-19b, U1 snRNA modification, KChIP2 histone regulation) are based on zebrafish or murine models. Human cardiac electrophysiology differs substantially (heart rate, Ito density, KCNH2 splicing ratios) — whether the specific magnitudes and directionality of these epigenetic effects are conserved in human disease is unconfirmed. (sources/genetics-va-fcvm-2022)
• H558R pleiotropic effects — protection vs. risk: SCN5A H558R reduces SCN5A promoter methylation and rescues BrS phenotype (protective), but the G allele is simultaneously associated with QTc prolongation (proarrhythmic). The net clinical effect of H558R in a given individual depends on the co-existing SCN5A variant background and possibly other modifier genes. This bidirectionality complicates interpretation of H558R in compound heterozygotes. (sources/genetics-va-fcvm-2022)
• KCNQ1OT1 imprinting and LQTS sex predominance — unresolved: KCNQ1OT1 regulation theoretically explains why KCNQ1-LQTS appears autosomal dominant (biallelic KCNQ1 expression in adult heart), yet clinical evidence of maternal transmission distortion and female predominance persists. Whether this represents incomplete epigenetic tissue specificity, residual imprinting in specific cardiac cell types, or a separate sex-hormone regulatory mechanism is not resolved. (sources/genetics-va-fcvm-2022)

Connections

• Related to concepts/Ion-Channel-Mutations
• Related to concepts/Cardiac-Action-Potential
• Related to concepts/GWAS-Cardiac-Genetics
• Related to concepts/AAV-Gene-Delivery
• Related to entities/Long-QT-Syndrome
• Related to entities/Brugada-Syndrome
• Related to entities/CPVT
• Related to entities/RYR2
• Related to entities/SCN5A

Sources

• sources/genetics-va-fcvm-2022